BiondVax Pharmaceuticals Ltd. (BVXV)
$1.7
-0.04 (-2.30%)
Rating:
Recommendation:
Buy
| Symbol | BVXV |
|---|---|
| Price | $1.7 |
| Beta | 2.462 |
| Volume Avg. | 0.03M |
| Market Cap | 5.583M |
| Shares () | - |
| 52 Week Range | 1.7-13.6 |
| 1y Target Est | - |
| DCF Unlevered | BVXV DCF -> | |
|---|---|---|
| DCF Levered | BVXV LDCF -> | |
| ROE | -219.57% | Strong Sell |
| ROA | -39.18% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 698.34% | Strong Buy |
| P/E | -0.44 | Neutral |
| P/B | 1.13 | Strong Buy |
Latest BVXV news
About
Download (Excel)Mr. Amir Reichman M.B.A., M.Sc.
Healthcare
Biotechnology
NASDAQ Capital Market
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.